In the News
Anti-competitive behaviour in market for hydrocortisone tablets
4th March 2017
On the surface this is a classic example of anti-competitive behaviour in a duopolistic market.
The CMA has alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. Naturally the announcement has brought a wave of criticism for the businesses involved because the cost of higher prices for drugs routinely used in the NHS are ultimately paid for by the taxpayer.
You can read more about the case here on the CMA website
Two pharmaceutical firms accused of driving up prices of an NHS life-saving drug with secret deal https://t.co/ovzRkL6P6j
— The Independent (@Independent) March 3, 2017
- Economics
- Blog
- In the News
- Anti-Competitive Behaviour
- Price fixing
- Competition and Markets Authority (CMA)
- Cartel
- Duopoly
Geoff Riley
Geoff Riley FRSA has been teaching Economics for over thirty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD conferences in the UK and overseas.
You might also like
Oligopoly - Collusion
Study Notes
Major tea exporters consider a new cartel
23rd January 2013
Revision on Producer Cartels
31st March 2012
Soap powder cartel leaves stain on colluders
13th April 2011
Business De-mergers
Study Notes
Competition and Markets Authority to investigate pie merger
20th December 2014
Duopoly
Study Notes
Oligopoly - What is Tacit Collusion?
Study Notes